Type 1 reaction in leprosy: a model for a better understanding of tissue immunity under an immunopathological condition

Expert Rev Clin Immunol. 2015 Mar;11(3):391-407. doi: 10.1586/1744666X.2015.1012501. Epub 2015 Feb 10.

Abstract

Type 1 reaction (T1R) or reversal reaction is the leading cause of physical disabilities and deformities in leprosy. Leprosy patients, even after being considered cured and released from treatment, may suffer from reactional episodes for long periods of time. Early diagnosis is a great challenge for effectively treating and managing T1R. There is an urgent need to identify the most significant biomarkers to prevent recurrent T1R and to differentiate late T1R from relapse. T1R continues to be treated with corticosteroids and complications due to iatrogenic treatment remain frequent. This review aims to provide a framework from which to approach the great challenges that still persist in T1R management and debate key issues in order to reduce the distance between basic research and the clinic.

Keywords: IFN-γ; Mycobacterium leprae; TNF-α; dendritic cells; leprosy; reversal reaction; type 1 reaction.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use*
  • Animals
  • Clinical Trials as Topic
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Interferon-gamma / antagonists & inhibitors
  • Leprostatic Agents / pharmacology
  • Leprostatic Agents / therapeutic use*
  • Leprosy / immunology
  • Leprosy / therapy*
  • Mycobacterium leprae / immunology*
  • Transforming Growth Factor beta / antagonists & inhibitors

Substances

  • Adrenal Cortex Hormones
  • Immunosuppressive Agents
  • Leprostatic Agents
  • Transforming Growth Factor beta
  • Interferon-gamma